NCT02168803View on ClinicalTrials.gov

A Study of Evacetrapib in Participants With Abnormal Cholesterol

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Dyslipidemia
Interventions
DRUG

Evacetrapib

Administered orally

Trial Locations (3)

32117

Covance Clinical Research Inc, Daytona Beach

53704

Covance Clinical Research Inc, Madison

75247

Covance, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02168803 - A Study of Evacetrapib in Participants With Abnormal Cholesterol | Biotech Hunter | Biotech Hunter